NXTC — NextCure, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2019-05-09.
Performance
Technicals
Others in Healthcare
Measured signals that fired on NXTC
| date | signal | measured base rate |
|---|---|---|
| 2026-08-12 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
| 2026-08-11 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-14 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-10 | Simcere Pharmaceutical Group Ltd | Open-market sale | 30.0K | 6.16 | 184.8K |
| 2026-08-10 | Ren Jinsheng | Open-market sale | 30.0K | 6.16 | 184.8K |
| 2026-08-10 | Simcere Zaiming Pharmaceutical Co., Ltd. | Open-market sale | 30.0K | 6.16 | 184.8K |
| 2026-08-10 | Simcere Zaiming, Inc. | Open-market sale | 30.0K | 6.16 | 184.8K |
| 2026-08-10 | Tang Renhong | Open-market sale | 30.0K | 6.16 | 184.8K |
| 2026-08-10 | Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | Open-market sale | 30.0K | 6.16 | 184.8K |
| 2026-07-31 | Schneeberger Daniel 10% owner | Open-market purchase | 25.0K | 4.98 | 124.5K |
| 2026-07-31 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | 25.0K | 4.98 | 124.5K |
| 2026-07-31 | Schneeberger Daniel 10% owner | Open-market purchase | 8.0K | 4.80 | 38.4K |
| 2026-07-31 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | 8.0K | 4.80 | 38.4K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Squadron Capital Management LLC | 2.8M | 265.0K |
| Affinity Asset Advisors, LLC | 2.6M | 241.8K |
| Ikarian Capital, LLC | 2.5M | 238.3K |
| Sofinnova Investments, Inc. | 2.4M | 222.7K |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.9M | 176.1K |
| Pfizer Inc | 1.5M | 153.4K |
| Opaleye Management Inc. | 1.5M | 141.2K |
| AWM Investment Company, Inc. | 1.2M | 117.4K |
| Exome Asset Management LLC | 1.2M | 115.5K |
| BOOTHBAY FUND MANAGEMENT, LLC | 743.5K | 69.6K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| S-4 | 2026-08-18 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-13 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-12 | — | on EDGAR ↗ |
| 4 | 2026-08-12 | 2026-08-10 | on EDGAR ↗ |
| 425 | 2026-08-10 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- NextCure, Inc. (NXTC) filed form S-4 · 2026-08-18 · SEC EDGAR
Ask the AI about NXTC
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →